Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

Courtney Woolsey, Joan B. Geisbert, Demetrius Matassov, Krystle N. Agans, Viktoriya Borisevich, Robert W. Cross, Daniel J. Deer, Karla A. Fenton, John H. Eldridge, Chad E. Mire, Thomas W. Geisbert

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

Original languageEnglish (US)
Pages (from-to)S582-S587
JournalJournal of Infectious Diseases
Volume218
DOIs
StatePublished - Nov 22 2018

Keywords

  • Angola
  • Marburg virus
  • Musoke
  • filovirus
  • recombinant vesicular stomatitis virus
  • treatment.
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates'. Together they form a unique fingerprint.

  • Cite this